source
- FDA approves zenocutuzumab for previously treated NRG1-fusion cholangiocarcinomaThe FDA has granted approval for zenocutuzumab to treat patients with previously treated, advanced cholangiocarcinoma that carries an NRG1 fusion. The decision was based on data from the eNRGy stud…
- Antibody-drug conjugates poised to move lung cancer treatment earlier, boosting response rates and targeting brain metastasesExperts highlight that antibody‑drug conjugates are reshaping non‑small cell lung cancer therapy, moving beyond their traditional role in later‑line settings. The new agents have demonstrated high…